Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for primary advanced or recurrent endometrial cancer:
- Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency (2025) NICE technology appraisal guidance 1117
- Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer (2025) NICE technology appraisal guidance 1092
- Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (2025) NICE technology appraisal guidance 1064
This page was last updated: